Neurology

EmailEmail    |   Bookmark Page Bookmark  |   RSS Feeds RSS  |   Print Page Print  

Karen Blindauer, MDKaren Ann Blindauer, MD

Associate Professor of Neurology
Director of Movement Disorders Program

Specialty: Adult Neurology
 

Sub Specialty:

  • Parkinson's Disease
  • Essential Tremor
  • Movement Disorders
  • Botulinum Toxin Injection for Dystonia
  • Deep Brain Stimulation (DBS)

Education:
 

  • Doctor of Medicine, Medical College of Wisconsin, Milwaukee, WI, 1993

Postgraduate Training and Fellowship Appointments:

  • Internal Medicine Internship, Medical College of Wisconsin, Milwaukee, WI, 1993 - 1994
  • Neurology Residency, Medical College of Wisconsin, Milwaukee, WI, 1994 - 1997
  • Movement Disorders and Experimental Therapeutics Fellowship, University of Rochester, Rochester, NY, 1997 - 1999

Societies:
 

  • American Academy of Neurology
  • American Medical Association
  • Movement Disorders Society

Awards/Honors:

  • Delta Sigma Nu Scholastic Honor Society, 1988
  • Scott Foundation Scholarship, 1989
  • Cornelius G. Dyke Award for Excellence in Neurology, 1993
  • David Fine MD Award for Excellence in Post Graduate Training, 1997
  • Alpha Omega Alpha Medical Honor Society, 1993
  • Dystonia Medical Research Foundation, Dystonia Doctor of Excellence Award, 2000
  • Selected for inclusion in Best Doctors of America

Brief Clinical/Research Interest Statement

  • Parkinson's Disease
  • Dystonia
  • Essential Tremor
  • Huntington's Disease

Current and Previous Research Projects

  • "A Multicenter, Randomized, Double-Blind, Parallel Group Pivotal Study Comparing TV1203/Carbidopa Dispersible Tablets with Levodopa/Carbidopa Tablets in Advanced PD Patients with Response Fluctuations", Project Co-Principal Investigator and Steering Committee Member, in collaboration with the University of Rochester Clinical Trials Coordination Center and the PSG, Teva Pharmaceuticals, sponsor.
  • "A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study for the Efficacy, Safety, and Tolerability of SPM-962 TDS in Patients with Early Parkinson's Disease"(PATCH 1), Project Co-Principal Investigator and Steering Committee Member, in collaboration with the University of Rochester Clinical Trials Coordination Center and the PSG, Schwarz Pharma, sponsor.
  • "A Multicenter, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability, and Safety of TVP-1012 in PD Patients with Fluctuations While Treated with Levodopa/Carbidopa", Steering Committee Member, in collaboration with the University of Rochester Clinical Trials Coordination Center and the PSG, Teva Pharmaceuticals, sponsor.
  • "Pilot Huntington at Risk Observational Study (PHAROS)", site Principal Investigator, in collaboration with the Huntington Study Group (HSG) and the University of Rochester Clinical Trials Coordination Center.
  • "Parkinson's Research: The Organized Genetics Initiative (PROGENI)", site Principal Investigator in collaboration with the Parkinson Study Group (PSG) and Indiana University.
  • "Identification of Splice Variants as Molecular Markers in Parkinson's Disease" (Principal investigator: Gloria E. Meredith, Ph.D.)
  • A randomized, double-blind, active and placebo controlled, efficacy study of pramipexole given 0.5mg and 0.75mg bid over a 12-week treatment phase in early Parkinson's disease patients (PramiBID)

Selected Publications

Original Publications:

  1. Blindauer K., Harrington G., Morris G. (1998). Fulminant Progression of Demyelinating Disease Following Valproate-Induced Hyperammonemic Encephalopathy, Neurology, 51(1):292-295.
  2. Moseley M, Benzow K, Schut L, Bird T, Gomez C, Barkhaus P, Blindauer K, Labuda M, Pandolfo M, Koob M, & Ranum L. (1998). Spinocerebellar ataxia types 1,2,3,6,7 and Friedreich's ataxia: incidence of trinucleotide expansions among 361 families with dominant, recessive, or sporadic forms of ataxia. Neurology51(6):1666-1671.
  3. Krouwer H, Kim T, Rand S, Prost R, Haughton V, Ho K-C, Jaradeh S, Blindauer K, Morris G, Meyer G, Walsh P, & Cusick J. (1998). Single Voxel Proton Magnetic Resonance Spectroscopy Suggestive of Tumor in Non-Neoplastic Central Nervous System Lesions, Am J Neuroradiology19:1695-1703.
  4. Siderowf A, McDermott M, Kieburtz K, Blindauer K, Plumb S, Shoulson I, and the Parkinson Study Group. "Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multi-center clinical trial", Movement Disorders. 17(4):758-63, July 2002.
  5. Parkinson Study Group. "A Controlled Trial of Rasagiline in early Parkinson Disease: the TEMPO Study", Archives of Neurology, 59(12):1937-43, Dec 2002. (Blindauer, K: Clinical trial steering committee member; study safety monitor; critical input in daily trial operations, data analysis, manuscript drafting and revision)
  6. Elsinger C, Rao S, Zimbelman J, Reynolds N, Blindauer K, and Hoffmann R. "Neural basis for impaired time reproduction in Parkinson's disease: An fMRI study", Journal of the International Neuropsychological Society. 9, 1088-1098, 2003.
  7. Blindauer, K, primary/corresponding author, and Parkinson Study Group. "A controlled trial of rotigotine monotherapy in early Parkinson's disease (PATCH study)", Archives of Neurology, 60:1721-1728, Dec 2003. (Co-Principal investigator of entire multi-center trial and steering committee member; critical role in study protocol development, clinical trial implementation, and data analysis; primary author)
  8. Blindauer, K, primary/corresponding author, and Parkinson Study Group. "A Randomized Controlled Trial of Etilevodopa in Parkinson's Disease Patients with Motor Fluctuations (RAPID study)", Archives of Neurology, 63:210-216, 2006. (Co-Principal investigator of entire multi-center trial and steering committee member; critical role in study protocol development, clinical trial implementation, and data analysis; primary author)
  9. Blindauer, K, primary/corresponding author and the Parkinson Study Group "Randomized Placebo-Controlled Study of the Nicotinic Agonist SIB-1508Y in Early Parkinson Disease", Neurology 66: 408-410, Feb 2006. (Clinical trial steering committee member; study safety monitor; critical input in daily trial operations, data analysis, manuscript drafting and revision)
  10. Biglan K, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D. Plumb S, Siderowf A, Stern M, Shoulson I, Parkinson Study Group. "Rasagiline improves quality of life in patients with early Parkinson's disease", Movement Disorders, 21:616-623, 2006. (Blindauer, K: Clinical trial steering committee member; critical input in study protocol and trial design, daily trial operations, data analysis, manuscript drafting and revision)
  11. deMarcaida JA, Schwid S, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I, et al. "Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline", Movement Disorders, 21: 1716-1721, October 2006.

Books, Chapters and Reviews:

  1. "Parkinson's Disease", in Current Therapy: Baker's Clinical Neurology, 2000 CD ROM edition, Lippincott, Williams, and Wilkins Publishers, R Joynt and RC Griggs, editors.
  2. "Myoclonus and its Disorders", in Neurologic Clinics, MB Stern and H Hurtig, editors, W.B. Saunders, Co.
  3. "Cerebellar Disorders and Spinocerebellar Ataxias," Neurology Continuum, 10(3): 154-173, June 2004.
  4. "Myoclonus", in Neurology Continuum, 10(3): 174-188, June 2004.
  5. "Spinocerebellar Ataxia 17", in Movement Disorders: 100 Instructive Cases, Stephen G. Reich, editor, Taylor and Francis Books, Ltd, in press.
webmaster@mcw.edu
© 2014 Medical College of Wisconsin
Page Updated 06/17/2014